University of Cambridge > > Darwin College Sciences Group > Designing novel therapeutics to inhibit oncogenic protein-protein interactions

Designing novel therapeutics to inhibit oncogenic protein-protein interactions

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Lorena Escudero.

The Anaphase promoting complex/ cyclosome (APC/C) is a 1.2 MDa multi-subunit E3 ubiquitin ligase that encodes broad substrate-specificity via its two co-activators Cdc20 and Cdh1 and three principal degrons: the D-box, KEN box and ABBA motif. The regulation of mitotic exit is tightly controlled by the expression and degradation of these two co-activators through stages of the cell cycle. The upregulation of Cdc20 is associated with many cancers including pancreatic,  breast and cervical cancers and hepatocellular carcinomas. However, to date,  no specific inhibitors of the APC /CCdc20 exist in the clinic. Only two APC /C specific compounds have been discovered: TAME /pro-TAME, which disrupts the C-terminal IR tail of Cdc20 binding to APC3 , and Apcin, which disrupts substrate D-box degron binding to Cdc20. Recent studies have highlighted the need for a combination strategy to achieve full inhibition of the APC /CCdc20. We propose a new approach involving the design of constrained peptides to inhibit key oncogenic protein-protein interactions with the APC /CCdc20,for the treatment of a wide range of cancers.

This talk is part of the Darwin College Sciences Group series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2017, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity